<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949361</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2017-01742</org_study_id>
    <nct_id>NCT03949361</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Long-term Administration: Effect on Cold Induced Energy Expenditure and Resting Metabolic Rate</brief_title>
  <acronym>GLACIER</acronym>
  <official_title>Glucocorticoid Long-term Administration: Effect on Cold Induced Energy Expenditure and Resting Metabolic Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ETH Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate whether treatment with glucocorticoids leads to a
      change in heat production of the human body at mild cold conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brown adipose tissue (BAT) is a thermogenic tissue that can convert chemical energy directly
      into heat due to the expression of uncoupling protein 1 (UCP1) protein. Data from preclinical
      studies shows that glucocorticoids (GCs) inhibit the function of BAT. In clinical practice
      GCs are often administered due tue their antiinflammatory properties making the investigation
      of short term (e.g. one week) and long therm (several months) effects practically relevant.
      This study's objective is to evaluate the effect of glucocorticoid treatment on cold induced
      thermogenesis (CIT) in humans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cold-induced thermogenesis (CIT) under glucocorticoids</measure>
    <time_frame>Change from glucocortoid start to +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of CIT change off-glucocorticoids with warm ischemia time (WIT) on-glucocorticoids by using indirect calorimetry. Comparing two Groups (Observation group A and B) we will address the CIT change from glucocorticoid start to 4-8 weeks into treatment (group A) and the CIT change from glucocorticoid therapy to weaning off upon more than 3 months after glucocorticoid withdrawal (group B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate (RMR)</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of RMR of patients starting GCs or patients stopping GCs, measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Comparison of body composition concerning muscle mass and fat mass, determined by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold stimulated glucose uptake into supraclavicular BAT</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Determination of 'standardized uptake value' (SUV) mean in two volumes of interest on the supraclavicular adipose tissue, after PET-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV max in supraclavicular adipose tissue depot</measure>
    <time_frame>Baseline and +4 to 8 weeks into treatment/ +3 months after weaning off GCs (resp.)</time_frame>
    <description>Determination of SUV max in the supraclavicular adipose tissue, after positron emission tomography (PET)-CT</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Thermoregulation Impairment</condition>
  <arm_group>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <description>Patients starting a glucocorticoid therapy measuring primary and secondary endpoints before and after at least 4 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
    <description>Patients stopping a glucocorticoid therapy measuring primary and secondary endpoints before weaning off glucocorticoids and after a period of at least 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <description>Resting energy expenditure</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin Temperature</intervention_name>
    <description>Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual energy X-ray Absorptiometry (DXA)</intervention_name>
    <description>Body composition</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <description>thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDG-PET</intervention_name>
    <description>Dynamic PET scanning of the neck-region</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Capillary glucose</intervention_name>
    <description>Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biopsy of supraclavicular adipose tissue (optional)</intervention_name>
    <description>Ultrasound guided biopsy of the supraclavicular adipose tissue</description>
    <arm_group_label>Patients starting glucocorticoids</arm_group_label>
    <arm_group_label>Patients stopping glucocorticoids</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma Optional biopsy of supraclavicular BAT
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited via the outpatient clinics (endocrinology, rheumathology,
        ophthalmology, gastroenterology etc.) of the Basel University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned therapy with at least 7.5 mg prednisone equivalent per day or higher for more
             than 28 days (group A)

          -  Planned weaning off glucocorticoid therapy which lasted al least 28 days with a dosage
             of at least 7.5 mg prednisone (group B)

          -  BMI 19-30 kg/m2

          -  Informed Consent as documented by signature

        Exclusion Criteria:

          -  Insufficient thyroid hormone substitution in case of hypothyroidism

          -  Uncontrolled diabetes mellitus (HbA1c &gt;7.5%)

          -  Severe concomitant diseases: chronic heart failure, liver cirrhosis, kidney failure,
             active cancer

          -  Known hypersensitivity to cold, e.g. primary or secondary Raynaud's Syndrome

          -  Known or suspected non-compliance

          -  Abuse of alcohol or illicit drugs

          -  Claustrophobia

          -  Women who are pregnant or breast feeding

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc of the participant

          -  Previous enrolment into the current study

          -  Enrolment into another study using ionizing radiation within the previous 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Matthias, PD Dr. med</last_name>
    <role>Study Director</role>
    <affiliation>Klinik Endokrinologie, Diabetes und Metabolismus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Matthias, PD Dr. med</last_name>
    <phone>0041 61 556 56 54</phone>
    <email>Matthias.Betz@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Maushart, Dr. med</last_name>
    <email>claudia.maushart@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Endocrinology</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias J Betz, MD</last_name>
      <phone>0041 61 265 5078</phone>
      <email>matthias.betz@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucocorticoids</keyword>
  <keyword>Brown Adipose tissue</keyword>
  <keyword>Cold Induced Thermogenesis</keyword>
  <keyword>Resting Metabolic Rate</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

